Under the agreement, both the parties will are expected to study pioglitazone, an active ingredient of Takeda‘s Actos (pioglitazone HCl) in connection with TOMM40 biomarker and alzheimer’s disease.
Further, Takeda Pharma is responsible to pay a sum of $9m as an upfront payment and up to $78m subsequent payments to Zinfandel as development milestones.
Additional commercial milestones and royalties were also outlined in the agreement.
The tie up allows Takeda Pharma to get an exclusive license, with the right to sublicense, develop, make, use and commercialize the TOMM40 biomarker assay, and to use the assay for the identification of high-risk older adults who would be candidates for clinical trials with pioglitazone to evaluate its utility.